Supplemental Methods, Figure 1,Tables 1-6 from Phase I Study of Oral Rigosertib (ON 01910.Na), a Dual Inhibitor of the PI3K and Plk1 Pathways, in Adult Patients with Advanced Solid Malignancies

Autor: Antonio Jimeno, Wells A. Messersmith, S. Gail Eckhardt, Manoj Maniar, Francois Wilhelm, Aik-Chook Tan, Chen Ren, Dara L. Aisner, Elizabeth Freas, Stephen B. Keysar, Brian W. Vogler, Marileila Varella-Garcia, Lia Gore, Stephen Leong, Ryan T. Anderson, David P. Astling, Colin D. Weekes, Elaine T. Lam, Jennifer R. Diamond, Daniel W. Bowles
Rok vydání: 2023
Popis: Supplemental Figure S1: Supplemental Figure 1 shows the pharmacokinetic plasma concentration curve following a single dose of oral rigosertib, revealing dose-dependent pharmacokinetics; Supplemental Table S1: This file provides individual patient characteristics, including demographics, time on study, best response, and duration of response; Supplemental Table S2: Adverse events, including the result of the adverse event (drug holding or dose reduction) are described for each patient; Supplemental Table S3: All serious adverse events are described in this file according to patient identification number, as is the relationship to rigosertib; Supplemental Table S4: This file gives the detailed results of multiplex mutation testing for each patient enrolled in this study whose tumor was analyzed; Supplemental Table S5: Validated exome sequencing results for patients with sensitive and resistant squamous cell carcinomas are described, including gene, position, and nucleotide affected; Supplemental Table S6: This file shows the exome sequencing coverage for each assessed squamous cell carcinoma.
Databáze: OpenAIRE